There are currently 2699 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
NCT03295981
Recruiting
The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Giant Cell Tumor of Bone
Register for Updates
A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
NCT04045470
Recruiting
This research is being done to study the safety of implanting and retrieving a microdevice that releases up to 19 drugs directly within a cancerous lesion as a possible tool to evaluate the effectiveness of several approved cancer drugs against cutaneous T cell lymphoma and peripheral T cell lymphoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Cutaneous T Cell Lymphoma, Peripheral T Cell Lymphoma
Register for Updates
The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia
NCT04598750
Recruiting
This is a prospective observational study designed to evaluate Immature Platelet Fraction or Immature Platelet Count and Platelet Function Analyzer-100/200 Closure Time-ADP (in vitro bleeding time) as markers of bleeding risk in thrombocytopenic preterm neonates admitted to the Neonatal Intensive Care Unit.
Gender:
ALL
Ages:
1 day and above
Trial Updated:
10/07/2024
Locations: Boston Children's Hospital, Boston, Massachusetts +1 locations
Conditions: Neonatal Thrombocytopenia, Bleeding
Register for Updates
Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: the SOLAR Trial
NCT04883671
Recruiting
The aim of this study is to learn whether the early initiation of a specialized and focused type of radiation called stereotactic body radiation therapy (SBRT) will impact the progression of advanced adenoid cystic carcinoma, quality of life, and overall survival. The name(s) of the study intervention involved in this study is: * Stereotactic Body Radiation Therapy (SBRT)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma
Register for Updates
Aspiration in Acute Respiratory Failure Survivors 2
NCT05108896
Recruiting
The purpose of this study is to learn more about problems with swallowing that could develop in patients who are very sick and need a machine to help them breathe.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Tufts Medical Center, Boston, Massachusetts +1 locations
Conditions: Dysphagia, Aspiration
Register for Updates
Prostate Cancer Genetic Risk Evaluation and Screening Study
NCT05129605
Recruiting
This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black/African ancestry and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with MRI will enable early detection and diagnosis of potentially aggressive prostat... Read More
Gender:
MALE
Ages:
Between 35 years and 74 years
Trial Updated:
10/05/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Prostatic Neoplasm, Prostate Cancer, BRCA2 Mutation, BRCA1 Mutation, ATM Gene Mutation, MMR Mutation, Lynch Syndrome, Genetic Predisposition to Disease
Register for Updates
Childhood Cancer Predisposition Study (CCPS)
NCT04511806
Recruiting
The Childhood Cancer Predisposition Study (CCPS) is a multi-center, longitudinal, observational study that will collect clinical and biological data and specimens from children with a cancer predisposition syndromes (CPS) and their relatives. The central hypothesis is that studying individuals at high risk for childhood cancer creates a unique opportunity for improving the understanding of carcinogenesis, tumor surveillance, early detection, and cancer prevention, which will collectively contri... Read More
Gender:
ALL
Ages:
All
Trial Updated:
10/03/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Pediatric Cancer
Register for Updates
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
NCT05926765
Recruiting
This study will assess the efficacy and safety of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
Register for Updates
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT05150691
Recruiting
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/02/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: HER2-positive Advanced Solid Tumor
Register for Updates
CEReBral AutorEgulation in Non-cardiac SuRgery and Relationship to Postoperative DeliriUm State
NCT06133842
Recruiting
The goal of this observational study is to learn the how to determine the mean arterial pressure(MAP) or blood pressure level to be maintained during non-cardiac surgery for optimal brain health in patients above the age of 60 undergoing major non-cardiac surgery. The main question\[s\] it aims to answer are: * Is there a way to tailor the blood pressure to be maintained in such patients during surgery for optimal brain health using non-invasive monitors that check the brains electrical activit... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
10/02/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Perioperative/Postoperative Complications, Postoperative Cognitive Dysfunction, Postoperative Delirium, EEG With Periodic Abnormalities, Intraoperative Hypotension, Cerebral Hypoperfusion
Register for Updates
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
NCT05544552
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations, including locally advanced/metastatic urothelial carcinoma of the bladder and urinary tract and other advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma, Solid Tumor, Adult, Bladder Cancer, Non-muscle-invasive Bladder Cancer, FGFR3 Gene Mutation, FGFR3 Gene Alteration, Advanced Solid Tumor, Advanced Urothelial Carcinoma, Urinary Tract Cancer, Urinary Tract Tumor, Urinary Tract Carcinoma
Register for Updates
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
NCT06160752
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma
Register for Updates